You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Bharat Biotech's Covaxin recognised by Australia for travelers

Hyderabad-based Bharat Biotech's Covaxin, and AstraZeneca and Oxford University's Covishield are the two widely used vaccines in India

Topics
Coronavirus Vaccine | Coronavirus | Australia

Press Trust of India  |  New Delhi 

Coronavirus vaccine

Australia's medicines and medical devices regulator on Monday formally recognised India's Covaxin, a vaccine against the as the country's border was reopened for the first time in nearly 20 months.

Hyderabad-based Bharat Biotech's Covaxin, and AstraZeneca and Oxford University's Covishield are the two widely used vaccines in India.

has already recognised Covishield.

"Today, the Therapeutic Goods Administration (TGA) determined that Covaxin (manufactured by Bharat Biotech, India) and BBIBP-CorV (manufactured by Sinopharm, China) vaccines would be 'recognised' for the purpose of establishing a traveller's vaccination status, Australia's medicines and medical devices regulator TGA said.

This recognition is for travellers aged 12 and over who have been vaccinated with Covaxin, and those 18 to 60 who have been vaccinated with BBIBP-CorV.

In recent weeks, the TGA has obtained additional information demonstrating these vaccines provide protection and potentially reduce the likelihood that an incoming traveller would transmit COVID-19 infection to others while in or become acutely unwell due to COVID-19.

The supporting information has been provided to the TGA from the vaccine sponsor and/or the World Health Organisation.

Importantly, recognition of Covaxin, and BBIBP-CorV, along with the previously announced recognition of Coronavac (manufactured by Sinovac, China) and Covishield (manufactured by AstraZeneca, India), means many citizens of China and India as well as other countries in our region where these vaccines have been widely deployed will now be considered fully vaccinated on entry to

This will have significant impacts for the return of international students, and travel of skilled and unskilled workers to Australia. TGA's updated report on its advice about vaccines not registered in Australia but in use internationally can be found at: COVID-19 vaccines not registered in Australia but in current international use - TGA advice on "recognition", the TGA said in a statement.

In addition, with input from the TGA, Australian Technical Advisory Group on Immunisation (ATAGI) have determined that those who have received two doses of a TGA-approved or recognised vaccine at least 14 days apart are regarded as fully vaccinated from 7 days after the second dose (with the exception of Janssen vaccine, where they are regarded as fully vaccinated 7 days after the single dose), it said.

This includes homologous (two doses of the same vaccine) and heterologous (two doses of two different TGA-approved or recognised vaccines) schedules, it added.

Today, the @TGAgovau determined that Covaxin (manufactured by @BharatBiotech,) vaccine would be 'recognised' for the purpose of establishing a traveller's vaccination status, Australia's High Commissioner to India Barry O'Farrell AO said on Twitter.

Importantly, recognition of #Covaxin, along with the previously announced recognition of #Covishield (manufactured by @AstraZenecaIn), means many citizens, as well as other countries, will now be considered fully vaccinated on entry to Australia, he said in another tweet.

Hyderabad-based Bharat Biotech, which has developed Covaxin, had submitted EOI (Expression of Interest) to the World Health Organisation on April 19 for the vaccine's Emergency Use Listing (EUL).

India's has been submitting data on the EUL of Covaxin regularly and very quickly to a technical committee which hopes to have a final recommendation to the WHO next week, a top official of the global health agency said on Thursday, stressing that the UN body "trusts" the Indian industry that manufactures high quality vaccines.

The WHO has so far approved Covid-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson & Johnson-Janssen, Moderna, and Sinopharm for emergency use.

Meanwhile, Australia's international borders reopened on Monday, ending nearly 20 months of tough restrictions and sparking emotional scenes at Sydney and Melbourne airports as people reunited with their loved ones.

At Sydney airport, passengers on flights from Singapore and Los Angeles were met with hugs and tears, the Australian media reported.

Australia was one of the first countries to shut its borders to international travel in March 2020 after the pandemic, which was first reported in central China's Wuhan city, peaked.

Shortly after the start of the pandemic, the government said only citizens and permanent residents would be allowed to enter, and they would have to undergo two weeks of hotel quarantine. A quota system also severely limited the number of people who could arrive each day.

But as Australia's vaccination rollout accelerated in recent months, Prime Minister Scott Morrison said citizens and permanent residents who had received both their shots would be allowed to travel internationally and return home from Monday -- with arrival quotas also lifted.

So far, only the highly-vaccinated states of New South Wales and Victoria -- home to Australia's largest cities of Sydney and Melbourne -- have relaxed restrictions on international arrivals. More than 80 per cent of the adult population in both states is now fully vaccinated, media reports said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, November 01 2021. 13:33 IST
RECOMMENDED FOR YOU